75 related articles for article (PubMed ID: 12817877)
21. WWOX--the FRA16D cancer gene: expression correlation with breast cancer progression and prognosis.
Płuciennik E; Kusińska R; Potemski P; Kubiak R; Kordek R; Bednarek AK
Eur J Surg Oncol; 2006 Mar; 32(2):153-7. PubMed ID: 16360296
[TBL] [Abstract][Full Text] [Related]
22. Germline BRCA1 mutations and G/C polymorphism in the 5'-untranslated region of the RAD51 gene in Polish women with breast cancer.
Romanowicz-Makowska H; Smolarz B; Kulig A
Pol J Pathol; 2005; 56(4):161-5. PubMed ID: 16477874
[TBL] [Abstract][Full Text] [Related]
23. Early detection of breast cancer based on gene-expression patterns in peripheral blood cells.
Sharma P; Sahni NS; Tibshirani R; Skaane P; Urdal P; Berghagen H; Jensen M; Kristiansen L; Moen C; Sharma P; Zaka A; Arnes J; Sauer T; Akslen LA; Schlichting E; Børresen-Dale AL; Lönneborg A
Breast Cancer Res; 2005; 7(5):R634-44. PubMed ID: 16168108
[TBL] [Abstract][Full Text] [Related]
24. Presence of erbB2 mRNA in the plasma of breast cancer patients is associated with circulating tumor cells and negative estrogen and progesterone receptor status.
Xu Y; Yao L; Li H; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Larsson O; Xie Y
Breast Cancer Res Treat; 2006 May; 97(1):49-55. PubMed ID: 16319978
[TBL] [Abstract][Full Text] [Related]
25. Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system.
Stathopoulou A; Gizi A; Perraki M; Apostolaki S; Malamos N; Mavroudis D; Georgoulias V; Lianidou ES
Clin Cancer Res; 2003 Nov; 9(14):5145-51. PubMed ID: 14613993
[TBL] [Abstract][Full Text] [Related]
26. [Germline mutation of BRCA1 gene in Polish families with strong aggregation of breast and/or ovarian cancer based on coding sequence analysis using the SSCP method].
Byrski T
Ann Acad Med Stetin; 2003; 49():27-43. PubMed ID: 15552838
[TBL] [Abstract][Full Text] [Related]
27. PCR analysis of matrix metalloproteinase 3 (MMP-3) gene promoter polymorphism in ovarian cancer.
Smolarz B; Szyłło K; Romanowicz-Makowska H; Niewiadomski M; Kozłowska E; Kulig A
Pol J Pathol; 2003; 54(4):233-8. PubMed ID: 14998290
[TBL] [Abstract][Full Text] [Related]
28. Ser326Cys polymorphism in DNA repair genes hOGG1 in breast cancer women.
Romanowicz-Makowska H; Smolarz B; Makowski M; Połać I; Pertyński T
Pol J Pathol; 2008; 59(4):201-4. PubMed ID: 19391486
[TBL] [Abstract][Full Text] [Related]
29. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
Egeli U; Cecener G; Tunca B; Tasdelen I
Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
[TBL] [Abstract][Full Text] [Related]
30. Two functionally relevant polymorphisms in the human progesterone receptor gene (+331 G/A and progins) and the predisposition for breast and/or ovarian cancer.
Romano A; Lindsey PJ; Fischer DC; Delvoux B; Paulussen AD; Janssen RG; Kieback DG
Gynecol Oncol; 2006 May; 101(2):287-95. PubMed ID: 16360811
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant chemotherapy for epithelial ovarian cancer--role of apoptosis.
Dutta T; Sharma H; Kumar L; Dinda AK; Kumar S; Bhatla N; Singh N
Cancer Chemother Pharmacol; 2005 Oct; 56(4):427-35. PubMed ID: 15906030
[TBL] [Abstract][Full Text] [Related]
32. Sister chromatid exchange rate and alkaline comet assay scores in patients with ovarian cancer.
Baltaci V; Kayikçioğlu F; Alpas I; Zeyneloğlu H; Haberal A
Gynecol Oncol; 2002 Jan; 84(1):62-6. PubMed ID: 11748978
[TBL] [Abstract][Full Text] [Related]
33. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
Metcalfe KA; Lynch HT; Ghadirian P; Tung N; Olivotto IA; Foulkes WD; Warner E; Olopade O; Eisen A; Weber B; McLennan J; Sun P; Narod SA
Gynecol Oncol; 2005 Jan; 96(1):222-6. PubMed ID: 15589605
[TBL] [Abstract][Full Text] [Related]
34. Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells.
Appierto V; Villani MG; Cavadini E; Gariboldi M; De Cecco L; Pierotti MA; Lambert JR; Reid J; Tiberio P; Colombo N; Formelli F
Oncogene; 2007 Jun; 26(27):3952-62. PubMed ID: 17213814
[TBL] [Abstract][Full Text] [Related]
35. MDR1 C3435T polymorphism in patients with breast cancer.
Turgut S; Yaren A; Kursunluoglu R; Turgut G
Arch Med Res; 2007 Jul; 38(5):539-44. PubMed ID: 17560460
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of necrosis in Nigerian breast cancer.
Ikpatt O; Ndoma-Egba R; Collan Y
Adv Clin Path; 2002 Jan; 6(1):31-7. PubMed ID: 17582946
[TBL] [Abstract][Full Text] [Related]
37. [Elevated expression of matrix metalloproteinase-9, and fibronectin concentration in recurrent epithelial ovarian cancer].
Demeter A; Szirmai K; Oláh J; Papp Z; Jeney A
Orv Hetil; 2004 Aug; 145(31):1617-24. PubMed ID: 15384859
[TBL] [Abstract][Full Text] [Related]
38. [The effect of sera of breast cancer patients on NK cell activity].
Konjević G; Spuzić I
Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
[TBL] [Abstract][Full Text] [Related]
39. Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance.
Connor JP; Felder M
Gynecol Oncol; 2008 Nov; 111(2):330-5. PubMed ID: 18723214
[TBL] [Abstract][Full Text] [Related]
40. Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer.
Webb PM; Hopper JL; Newman B; Chen X; Kelemen L; Giles GG; Southey MC; Chenevix-Trench G; Spurdle AB
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):319-23. PubMed ID: 15734952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
